ProHealth health Vitamin and Natural Supplement Store and Health
Home  |  Log In  |  My Account  |  View Cart  View Your ProHealth Vitamin and Supplement Shopping Cart
800-366-6056  |  Contact Us  |  Help
Facebook Google Plus
Fibromyalgia  Chronic Fatigue Syndrome & M.E.  Lyme Disease  Natural Wellness  Supplement News  Forums  Our Story
Store     Brands   |   A-Z Index   |   Best Sellers   |   New Products   |   Deals & Specials   |   Under $10   |   SmartSavings Club

Trending News

10 Fibro-Friendly Foods with a Bonus: Beautiful Skin

Fight Back! Win the War Being Waged Against Your Immune System

Studies Show that Magnesium L-threonate Improves Brain Plasticity, Leading to Direct and Significant...

Clary Sage Oil May Be Pricey, but Its Benefits Are Priceless

Component of red wine, grapes can help to reduce inflammation, study finds

Poly MVA: A Novel Therapy for Increasing Energy, Repairing DNA, and Promoting Overall Health

Pumpkin Pie Turmeric Breakfast Smoothie - Vegan + Gluten-Free

Vitamin D supplementation extends life in mouse model of Huntington's disease

What’s Fenugreek Good For?

Omega-3 fatty acid stops known trigger of lupus

Print Page
Email Article

Protein Holds Promise as New Diabetes Drug Target

  [ 58 votes ]   [ Discuss This Article ] • July 18, 2003

Basic science, decades in the works, pays off in discovery
Scientists at the pharmaceutical company Hoffman-La Roche have discovered a chemical compound that activates the glucokinase enzyme and that could lead to a new medication for type 2 diabetes. Their work, reported in the July 18 issue of Science, builds on basic science performed at Vanderbilt University Medical Center that started 18 years ago.

When Dr. Mark A. Magnuson arrived at Vanderbilt in 1985 as a postdoctoral fellow, he took on a challenging project – cloning the gene for the enzyme glucokinase. At the time, it was known that glucokinase was important for the metabolism of glucose, the sugar that climbs dangerously high in the blood of patients with diabetes. The cloning project was a success, and now, with the work by Hoffman-La Roche, glucokinase is taking center stage as a new drug target for type 2 diabetes.

"There have not been that many new drugs for the treatment of diabetes ever discovered, and this one is unique in its mechanism of action," said Magnuson, assistant vice chancellor for Research and a co-author of the report. "By turning on glucokinase, this novel compound improves insulin secretion by the pancreas and stimulates glucose usage by the liver, both of which are abnormal in diabetes." Magnuson cautions that it's too early to tell what the real value of a glucokinase-activating drug might be. Clinical trials are still in the planning stage. "It has dramatic effects in animals, suggesting it has the potential to be a very powerful new drug," he said.

The promise of such a drug comes from its target, glucokinase. This enzyme – a "glucose sensor" – plays a key role in maintaining sugar balance in the body. It acts mainly in the pancreatic beta cell, where it is important for insulin secretion, and in the liver, where it participates in how glucose is used and stored. Because both insulin secretion and glucose utilization by the liver are defective in patients with diabetes, a single drug that improves both functions is an attractive possibility, Magnuson said.

In the years since they cloned the glucokinase gene, Magnuson and Dr. Daryl K. Granner, director of the Vanderbilt Diabetes Center – joined by several other Vanderbilt laboratories along the way – have ferreted out nuances of how the enzyme works. Most recently, Magnuson and colleagues have genetically engineered mice that lack glucokinase only in selected tissues, like the beta cell or liver, to understand tissue-specific roles and regulation.

"Studies performed at Vanderbilt were essential for demonstrating the importance of this enzyme," Magnuson said.

After the glucokinase gene was cloned, other investigators identified mutations in the human gene. Mutations that cause the enzyme not to function properly have been linked to a form of diabetes called maturity-onset diabetes of the young type 2 (MODY2). And mutations that activate glucokinase – much like the newly discovered compound – cause persistent hyperinsulinemic hypoglycemia of infancy, a condition characterized by high insulin and low blood glucose. These observations solidified the view that glucokinase would be an ideal target for an antidiabetic drug, Magnuson said.

Even so, he added, "no one ever thought we would find a drug that directly targets the enzyme and activates it." The investigators at Hoffman-La Roche were actually screening for compounds that would work in an indirect way to alter glucokinase activity when they found the chemical described in the Science report.

"It was a serendipitous discovery," Magnuson said. "One compound in one of their chemical libraries (of over 120,000 compounds) happened to bind to and activate glucokinase." Other companies that have also been searching for compounds to affect glucokinase activity have not been so fortunate, he said.

The Hoffman-La Roche team demonstrated that the new compound enhances insulin release from isolated rat pancreatic islets. It also lowers blood glucose levels and improves results of oral glucose tolerance tests in rats and mice with diabetes.

Though it will be several more years before clinical trials begin to reveal whether or not drugs based on this compound are effective therapies for diabetes, Magnuson marvels at the progress that's been made since the glucokinase cloning project first got started.

"It really emphasizes the value of basic science research, and how studying enzymes and the mechanisms for regulation of blood glucose can yield important clues and unpredicted things that pay out over time," he said. "Now we're beginning to see the promise of some very basic science research that was done here at Vanderbilt."

Post a Comment

Featured Products From the ProHealth Store
Optimized Curcumin Longvida® Vitamin D3 Extreme™ Mitochondria Ignite™ with NT Factor®

Looking for Vitamins, Herbs and Supplements?
Search the ProHealth Store for Hundreds of Natural Health Products

Article Comments

Be the first to comment on this article!

Post a Comment

Natural Pain Relief Supplements

Featured Products

Optimized Curcumin Longvida® Optimized Curcumin Longvida®
Supports Cognition, Memory & Overall Health
Ultra EPA  - Fish Oil Ultra EPA - Fish Oil
Ultra concentrated source of essential fish oils
Vitamin D3 Extreme™ Vitamin D3 Extreme™
50,000 IU Vitamin D3 - Prescription Strength
Energy NADH™ 12.5mg Energy NADH™ 12.5mg
Improve Energy & Cognitive Function
Ultra ATP+, Double Strength Ultra ATP+, Double Strength
Get energized with malic acid & magnesium

Natural Remedies

Guarding Against the Dangers of Vitamin D Deficiency Guarding Against the Dangers of Vitamin D Deficiency
Magnesium + Malic Acid: One-Two Punch for Pain & Fatigue Magnesium + Malic Acid: One-Two Punch for Pain & Fatigue
The Brain Boosting and Fatigue Fighting B-12 The Brain Boosting and Fatigue Fighting B-12
Safely Burn Away Body Fat Safely Burn Away Body Fat
How I Found My Long-Lost Energy How I Found My Long-Lost Energy

ProHealth, Inc.
555 Maple Ave
Carpinteria, CA 93013
(800) 366-6056  |  Email

· Become a Wholesaler
· Vendor Inquiries
· Affiliate Program
Credit Card Processing
Be the first to know about new products, special discounts and the latest health news. *New subscribers only

CONNECT WITH US ProHealth on Facebook  ProHealth on Twitter  ProHealth on Pinterest  ProHealth on Google Plus

© 2016 ProHealth, Inc. All rights reserved. Pain Tracker App  |  Store  |  Customer Service  |  Guarantee  |  Privacy  |  Contact Us  |  Library  |  RSS  |  Site Map